Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system. Potential targets for therapy?

European Heart Journal

Volumn 20, Issue 6, 1999, Pages 406-420

  Li, J M ^a   Brooks, G ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Cardiac myocyte; Cyclin; Cyclin dependent kinase; Cyclin dependent kinase inhibitor; Hypertrophy; Vascular smooth muscle cell

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN P21; VIRUS VECTOR;

CARDIOVASCULAR SYSTEM; CELL CYCLE; DRUG TARGETING; GENE TRANSFER; HEART DEVELOPMENT; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 0033048656     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1308     Document Type: Review

References (124)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 266:1994;1821-1828.
2. Hutchison C, Glover DM. Cell cycle control. 1995;Oxford University Press, New York.
3. Tyson JJ, Novak B, Odell GM, Chen K, Thron CD. Chemical kinetic theory: understanding cell-cycle regulation. TIBS. 21:1996;89-95.
4. Brooks R, Fantes P, Hunt T, Wheatley D. The cell cycle. 1989;The Company of Biologists Ltd. Cambridge.
5. McGill CJ, Brooks G. Cell cycle control mechanisms and their role in cardiac growth. Cardiovascular Res. 30:1995;557-569.
6. Martinez A-M, Afshar M, Martin F, Cavadore J-C, Labbe J-C, Doree M. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity. EMBO J. 16:1997;343-354.
7. Anderson G, Busso D, Poterszman A. The structure of cyclin H: common mode of kinase activation and specific feature. EMBO J. 16:1997;958-967.
8. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J. G1 control in mammalian cells. J Cell Sci Suppl. 18:1994;69-73.
9. Pines J. Cyclin-dependent kinase inhibitors: the age of crystals. Biochem Biophys Acta. 1332:1997;M39-M42.
10. Brooks G, Poolman RA, Li J-M. Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors. Cardiovasc Res. 39:1998;301-311.
11. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 213:1996;138-149.
12. Prives C. Doing the right think: feedback control and p53. Curr Opin Cell Biol. 5:1993;214-218.
13. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature. 381:1996;643-644.
14. Ewen ME. p53-dependent repression of cdk4 synthesis in transforming growth factor-β-induced G1 cell arrest. J Lab Clin Med. 128:1996;355-360.
15. CIP1. Nature. 375:1995;159-161.
16. Knibiehler M, Goubin F, Escales N. Interaction studies between the p21Cip1/Waf1 cyclin-dependent kinase inhibitor and proliferating cell nuclear antigen (PCNA) by surface plasmon resonance. FEBS Lett. 391:1996;66-70.
17. Waga S, Hannon GL, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
18. Taya Y. RB kinases and RB-binding proteins: new points of view. TIBS. 22:1997;14-17.
19. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
20. Nevins JR. E2F: a link between the Rb tumour suppressor protein and viral oncoproteins. Science. 258:1992;424-429.
21. Woo MS-A, Sanchez I, Dynlacht BD. p130 and p107 use a converted domain to inhibit cellular cyclin-dependent kinase activity. Mol Cell Biol. 17:1997;3566-3579.
22. INK4A. Mol Cell Biol. 16:1996;1047-1057.
23. Girling R, Partridge JF, Bandara LR. A new component of the transcription factor DRTF1/E2F. Nature. 362:1997;83-87.
24. Wu C-L, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol Cell Biol. 15:1995;2536-2546.
25. Dynlacht BD, Moberg K, Lees JA, Harlow E, Zhu L. Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol. 17:1997;3867-3875.
26. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene. 14:1997;1191-1200.
27. Fry CJ, Slanksy JE, Farnham PJ. Position-dependent transcriptional regulation of the murine dihydrofolate reductase promoter by the E2F transactivation domain. Mol Cell Biol. 17:1997;1966-1976.
28. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-808.
29. Coronado B, Griffith JL, Beshansky JR, Selker HP. Hospital mortality in women and men with acute cardiac ischaemia: a prospective multicenter study. J Am Coll Cardiol. 29:1997;1490-1496.
30. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation. 83:1991;402-411.
31. MacLeod DC, Strauss BH, de Jone M. Proliferation and extracellular matrix synthesis of smooth muscle cell cultures from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 23:1994;59-65.
32. Simons M. Therapeutic manipulation of cell cycle in smooth muscle cells: Implications for restenosis. J Lab Clin Med. 128:1996;361-366.
33. McEwan J. Vascular disease: the next target for local molecular therapeutics. BMJ. 308:1994;995-996.
34. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamysin - FKBP inhibits cell cycle regulation of proliferation in vascular smooth muscle cells. Circ Res. 76:1995;412-417.
35. Watson MH, Venance SL, Pang SC, Mak AS. Smooth muscle proliferation. Circ Res. 73:1992;109-117.
36. Shimokado K, Umezawa K, Ogata J. Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Exp Cell Res. 220:1995;266-273.
37. KIP1. J Clin Invest. 99:1997;2334-2341.
38. Reddy KB, Howe PH. Transforming growth factor β1-mediated inhibition of smooth muscle cell proliferation is associated with a late G1 cell cycle arrest. J Cellular Physiol. 156:1993;48-55.
39. Tsai J-C, Wang H, Perrella MA. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 97:1996;146-153.
40. Malam-Souley R, Seye C, Gadeau A-P. Nucleotide receptor p2u partially mediates ATP-induced cell cycle progression of aortic smooth muscle cells. J Cell Physiol. 166:1996;57-65.
41. Lubec B, Labudova O, Hoeger H. Homocysteine increase cyclin-dependent kinase in aortic rat tissue. Circulation. 94:1996;2620-2625.
42. Koyama H, Nishizama Y, Hosoi M. The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-1. Circ Res. 79:1996;757-764.
43. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 87:1996;1069-1078.
44. Sasaguri T, Ishida A, Kosaka C, Nojima H, Ogata J. Phorbol ester inhibits the phosphorylation of the retino-blastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells. J Biol Chem. 271:1996;8345-8351.
45. Philpott A, Porro EB, Kirschner MW, Tsai L-H. The role of cyclin-dependent kinase 5 and a novel regulatory subunit in regulating muscle differentiation and patterning. Genes Dev. 11:1997;1409-1421.
46. Lentz SR. Homocysteine and vascular dysfunction. Life Sci. 61:1997;1205-1215.
47. Datto MB, Yu Y, Wang X-F. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem. 268:1995;28623-28628.
48. Reynisdottir I, Massague J. The subcellular locations of p15 (Ink4b) and p27 (Kip1) coordinate their inhibitory inter-actions with cdk4 and cdk2. Genes Dev. 11:1997;492-503.
49. Wei GL, Krasinksi K, Kearney M, Isner JM, Walsh K, Andres V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 80:1997;418-426.
50. Sylvester AM, Chen D, Krasinski K, Andres V. Role of c-fos. J Clin Invest. 101:1998;940-948.
51. Bennett MR, Macdonald K, Chan S-W, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res. 82:1998;704-712.
52. Tanner FC, Yang Z-Y, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 82:1998;396-403.
53. Abe J, Zhou W, Takuwa N. A fumagillin derivative angiogenesis inhibitor: AGM-1470, inhibits activation of cyclin-dependent kinase and phosphorylation of retino-blastoma gene product but not protein tyrosyl phosphory-lation or protooncogene expression in vascular endothelial cells. Cancer Res. 54:1994;3407-3412.
54. Hori A, Ikeyama S, Sudo K. Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-1470 (AGM-1470) in vascular endothelial cells. Biochem Biophys Res Commun. 204:1994;1067-1073.
55. Zhou W, Takuwa N, Kumada M, Takuwa Y. Protein kinase C-mediated bidirectional regulation of DNA synthesis, RB protein phosphorylation, and cyclin-dependent kinases in human vascular endothelial cells. J Biol Chem. 268:1993;23041-23048.
56. Zhou W, Takuwu N, Kumada M, Takuwa Y. E2F1, B-myb and selective members of cyclin/CDK subunits are targets for protein kinase C-mediated bimodal growth regulation in vascular endothelial cells. Biochem Biophys Res Commun. 199:1994;191-198.
57. Kosaka C, Sasaguri T, Ishida A, Ogata J. Cell cycle arrest in the G2 phase induced by phorbol ester and diacylglycerol in vascular endothelial cells. Am J Physiol. 270:1996;C170-8.
58. Yoshizumi M, Hsieh C-M, Zhou F. The ATF site mediates downregulation of the cyclin A gene during contact inhibition in vascular endothelial cells. Mol Cell Biol. 15:1995;3266-3272.
59. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis. Circulation. 92:1995;1981-1993.
60. Isner JM. Oligonucleotide therapeutics - novel cardiovascular targets. Nature Med. 3:1997;834-835.
61. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 75:1996;313-323.
62. Mann MJ, Gibbons GH, Kernoff RS. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA. 92:1995;4502-4506.
63. Morishita R, Gibbons GH, Ellison KE. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 90:1993;8474-8478.
64. Morishita R, Gibbons GH, Ellison KE. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest. 93:1994;1458-1464.
65. Abe J-I, Zhou W, Taguchi J-I. Suppression of neo-intimal smooth cell accumulation by antisense cdc2 and CDK2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun. 198:1994;16-24.
66. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 149:1994;13-19.
67. Mann MJ, Gibbon GH, Tsao PS. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest. 99:1997;1295-1301.
68. Suzuki J-I, Isobe M, Morishita R. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligo-nucleotide. Nature Med. 3:1997;900-903.
69. Morishita R, Sugimoto T, Aoki M. In vivo transfection ofcis. Nature Med. 3:1997;894-899.
70. Morishita R, Gibbons GH, Horiuchi M. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA. 92:1995;5855-5859.
71. Yang Z-Y, Simari RD, Perkins ND. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA. 93:1996;7905-7910.
72. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 96:1997;2260-2268.
73. Chang MW, Barr E, Seltzer J. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
74. Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL. Adeno-associated virus vectors for vascular gene delivery. Circ Res. 80:1997;497-505.
75. Zhu NL, Wu L, Liu PX. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cells proliferation and neointima formation. Circulation. 96:1997;628-635.
76. Harrell RL, Rajanayagam S, Doanes AM. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 96:1997;621-627.
77. Matsushita H, Morishita R, Kida I. Inhibition of growth of human vascular smooth muscle cells by over-expression of p21 gene through induction of apoptosis. Hypertension. 31:1998;493-498.
78. Yonemitsu Y, Kaneda Y, Tanaka S. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res. 82:1998;147-156.
79. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res. 83:1998;1-14.
80. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 83:1998;15-26.
81. Brooks G, Poolman RA, McGill CJ, Li J-M. Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes. J Mol Cell Cardiol. 29:1997;2261-2271.
82. Li J-M, Brooks G. Down-regulation of the cyclin dependent kinase inhibitors, p21 and p27, in pressure overload hypertrophy. Am J Physiol. 273:1997;H1358-67.
83. Poolman RA, Brooks G. Expression of CIP/KIP family of cyclin-dependent kinase inhibitors during cardiac development (Abstr). Circulation. 94:1996;A0909.
84. Yoshizumi M, Lee W-S, Hsieh C-M. Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest. 95:1995;2275-2280.
85. Sadoshima J, Aoki H, Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 80:1997;228-241.
86. Burton PBJ, Yacoub MH, Barton PJR. Cell cycle regulatory molecule expression during heart development (Abstr). J Mol Cell Cardiol. 29:1997;A41.
87. Horky M, Kuchtickova S, Vojtesek B, Kolar F. Induction of cell-cycle inhibitor p21 in rat ventricular myocytes during early postnatal transition from hyperplasia to hypertrophy. Physiol Res. 46:1997;233-235.
88. Kang MJ, Kim J-S, Chae S-W, Koh KN, Koh GY. Cyclins and cyclin dependent kinases during cardiac development. Mol Cells. 7:1997;360-366.
89. Flink IL, Oana S, Maitra N, Bahl JJ, Morkin E. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. J Mol Cell Cardiol. 30:1998;563-578.
90. Kang MJ, Koh GY. Differential and dramatic changes of cyclin-dependent kinase activities in cardiomyocytes during the neonatal period. J Mol Cell Cardiol. 29:1997;1767-1767.
91. KIP1. J Mol Cell Cardiol. 30:1998;463-474.
92. Poolman RA, Brooks G. CIP/KIP cyclin-dependent kinase inhibitor (CDKI) expression during cardiac myocyte development (Abstr). J Mol Cell Cardiol. 29:1997;A19.
93. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol. 28:1996;1737-1746.
94. van Bilsen M, Chien KR. Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression. Cardiovasc Res. 27:1993;1140-1149.
95. Frohlich ED, Apstein C, Chobanian AV. The heart in hypertension. N Engl J Med. 327:1992;998-1008.
96. Chevalier B, Amrani FC-E, Heymes C, Swynghedauw B. Molecular basis of regression of cardiac hypertrophy. Am J Cardiol. 73:1994;10C-17C.
97. Schneider MD. Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes? J Cardiac Failure. 2:1996;259-263.
98. Li J-M, Brooks G. Expression of cyclin dependent kinase inhibitors, p21 and p27, during cardiac hypertrophy in rats (Abstr). Circulation. 94:1996;1-551.
99. Li J-M, Poolman RA, Brooks G. Involvement of G1 phase cyclins and cyclin dependent kinases during hypertrophic growth of adult rat cardiomyocytes. Am J Physiol. 275:1998;H814-H822.
100. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5:1991;3037-3046.
101. Parker TG, Packer SE, Schneider MD. Peptide growth factor can provoke 'fetal' contractile protein gene expression in rat cardiac myocytes. J Clin Invest. 85:1991;507-514.
102. Li J-M, Brooks G. Differential protein expression and subcellular distribution of TGFβ1, β2 and β3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol. 29:1997;2213-2224.
103. Chen WH, Pellegata NS, Wang PH. Coordinated effects of insulin-like growth factor on inhibitory pathways of cell cycle progression in cultured cardiac muscle cells. Endocrinology. 136:1995;5240-5243.
104. Koh GY, Klug MG, Soonpaa MH, Field LJ. Differentiation and long-term survival of c2c12 myoblast grafts in heart. J Clin Invest. 92:1993;1548-1554.
105. Leo J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. Circulation. 94:1996;II332-6.
106. Scorsin M, Marotte F, Sabri A. Can grafted cardiomyocytes colonize peri-infarct myocardial areas? Circulation. 94:1996;II337-40.
107. Chien KR. Cardiac muscle disease in genetically engineered mice: evolution of molecular physiology. Am J Physiol. 169:1997;H755-66.
108. Kirshenbaum LA, Abdellatif M, Chakroborty S, Schneider MD. Human E2F-1 reactives cell cycle progression in ventricular myocytes and represses cardiac gene transcription. Dev Biol. 179:1996;402-411.
109. Agah R, Kirshenbaum LA, Abdellatif M. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. J Clin Invest. 100:1997;2722-2728.
110. Kirshenbaum LA, Schneider MD. Adenovirus E1A repress cardiac gene transcription and reactives DNA synthesis in ventricular myocytes, via alternative pocket protein- and p300-binding domains. J Biol Chem. 270:1995;7791-7794.
111. Liu Y, Kitsis RN. Induction of DNA synthesis and apoptosis in cardiac myocytes by E1A oncoprotein. J Cell Biol. 133:1996;325-334.
112. Hasegawa K, Meyers MB, Kitsis RN. Transcriptional coactivator p300 stimulates cell type-specific gene expression in cardiac myocytes. J Biol Chem. 272:1997;20049-20054.
113. Bishopric NH, Zeng GQ, Sato B, Webster KA. Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus. J Biol Chem. 272:1997;20584-20594.
114. Soonpaa MH, Koh GY, Pajak L. Cyclin D1 over-expression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest. 99:1997;2644-2654.
115. Nakayama K, Ishida N, Shirane M. Mice lacking p27 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumours. Cell. 85:1996;707-720.
116. Poolman RA, Li J-M, Brooks G. Altered expression of cell cycle regulatory protein in p27 knockout mice (Abstr). Circulation. 96:1997;I6.
117. Nigg EA. Cellular substrates of p34cdc2 and its companion cyclin-dependent kinase. Trends Cell Biol. 3:1993;296-301.
118. Solomon M. Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol. 5:1993;180-186.
119. Hoffmann I, Karsenti E. The role of cdc25 in checkpoints and feedback controls in the eukaryotic cell cycle. J Cell Sci Supply. 18:1994;75-79.
120. Wuarain J, Nurse P. Regulating S phase: CDKs, licensing and proteolysis. Cell. 85:1996;785-787.
121. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol. 16:1996;1126-1137.
122. Katayose D, Wersto R, Cowan K, Seth P. Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells. Biochem Biophys Res Commun. 215:1995;446-451.
123. WAF1/CIP1. J Clin Invest. 98:1996;426-433.
124. Simons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in rat carotid artery injury model. J Clin Invest. 93:1994;2351-2356.